This article is more than 5 years old. Information may no longer be current.
The Disappearance of 'Special' Populations
Click Here to Manage Email Alerts
New drug developments for the treatment of patients with hepatitis C virus infection are redefining the characterization of so-called “special populations.” The idea for the October issue cover story was spurred by a talk on HCV given by HCV Next Editorial Board member Nancy S. Reau, MD, at Digestive Disease Week 2014 in May. There, Reau told the audience: “Special populations are no longer special.”
In this issue, read more about the reasons why Reau and other experts in HCV believe that special populations are becoming a thing of the past, and also which patient populations continue to present clinical challenges.
Also in this issue, the feature presents an in-depth look at a new update to the HCVguidelines.org website, with guidance from the American Association for the Study of Liver Diseases and Infectious Disease Society of America, in collaboration with the International Antiviral Society-USA, on when and in whom to initiate HCV therapy.
New this month is the Meeting News Coverage section, which presents coverage from major medical conferences important to the readers of HCV Next. This month, we offer news from the Interscience Conference on Antimicrobial Agents and Chemotherapy, held in September. Coming soon, expect to read more news from the American College of Gastroenterology Annual Scientific Meeting and The Liver Meeting. HCV Next staff will be onsite at both of those meetings this fall, bringing breaking headlines back to you in print and online.